UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations in the US each year, GSK said.

The FDA has accepted for Priority Review the sBLA for aflibercept injection 8mg for the treatment of macular edema following RVO and for monthly dosing in approved indications.